Oncology News | pharmaphorum

News

ESMO: J&J cues up phase 3 for Rybrevant in colorectal cancer

Johnson & Johnson is planning a phase 3 programme for Rybrevant in colorectal cancer as a follow-up to its first indication in non-small cell lung cancer (NSCLC), after reporting encour

News

ESMO: NIAGARA backs Imfinzi in bladder cancer, but will FDA?

AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder cancer (MIBC) that it hopes will be enough to secure FDA approval – although the jury is out on that.

News

Natasha Dawson of the Ella Dawson Foundation outside the Royal Marsden Hospital

Support app for young cancer patients launches in UK

Rates of cancer among people aged 24 and below are rising fast, but health systems are often not catering well enough to the specific needs of this age group.

News

ESMO: Incyte's PD-1 treads new ground in anal cancer

Incyte's first attempt to get FDA approval for its PD-1 inhibitor Zynyz for squamous cell carcinoma of the anal canal (SCAC) was knocked back by the FDA, but new data could get the programm

News

ESMO: GSK, iTeos bring some optimism back to TIGIT

GSK and iTeos anti-TIGIT antibody belrestotug showed efficacy in a phase 2 trial in PD-L1-positive non-small cell lung cancer (NSCLC), providing some much-needed positive news for the belea

News

ESMO: Enhertu shows its worth in brain metastases

Women with HER2-positive breast cancer can be treated with AstraZeneca and Daiichi Sankyo's Enhertu, regardless of whether their cancer has spread to the brain, according to a new study.

ESMO: J&J cues up phase 3 for Rybrevant in colorectal cancer

ESMO: NIAGARA backs Imfinzi in bladder cancer, but will FDA?

Support app for young cancer patients launches in UK

ESMO: Incyte's PD-1 treads new ground in anal cancer

ESMO: GSK, iTeos bring some optimism back to TIGIT

ESMO: Enhertu shows its worth in brain metastases

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

News

Editor's Picks